AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02720874 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monthly healthcare coordinator calls
Description: During monthly calls with the healthcare coordinator, specific questions and concerns raised by participants may be addressed. The primary purpose of these calls is to control for potential benefit derived from time on the phone with a health professional.
Study NCT02720874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-based symptom monitoring and reporting
Description: When at home patient self-monitoring reports indicate a significant increase in RA disease activity, participants will be promptly contacted and scheduled for an ad hoc evaluation with their treating rheumatologist.
Study NCT05594264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HBPStories
Description: The objective of this arm was to pilot test the web-based storytelling program to determine the preliminary impact on blood pressure and medication adherence, and if the web-based approach was an engaging approach for individuals managing hypertension.
Study NCT06374758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Accelerate model of care
Description: Contact is established by the study team~The patient is provided with a telehealth appointment with an HIV care provider within 24 business hours of contact~At the time of enrollment/initial clinic visit, patients who meet the inclusion and exclusion criteria will be enrolled in the study~The HIV care provider will prescribe B/F/TAF to their pharmacy of choice.~B/F/TAF is dispensed by the designated study pharmacist and mailed to the patient as a free 30-day starter pack to allow time for benefits verification.~A telephone follow-up call by the study team will be conducted within 2 - 4 weeks from the initial clinical visit to assess any adverse events, tolerability, and adherence.~Hand-off to HIV clinic to establish care within 4 weeks. Lab results will be drawn during clinic per HIV care provider which might include CBC, CMP, HIV-1 RNA, CD4, and genotype resistance testing when clinically indicated by the HIV care provider.
Study NCT06374758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg
Description: Same as above, it is the same intervetion
Study NCT05873829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand-foot exercises
Description: Hand-foot exercise program consists of 5 hand and 5 foot exercises, and a total of 15 minutes of simple hand-foot exercises. The exercise program is applied 3 times a day, 3 days a week. The tennis ball and the towel that used in the exercise program, the booklet which containing the exercise explanations and the video link showing the implementation of the exercises were provided by the researcher.
Study NCT05933395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus will be administered orally in tablet form once daily in combination with fulvestrant administration as outlined above.
Study NCT05933395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib will be administered orally in tablet form twice daily in combination with fulvestrant administration as outlined above.
Study NCT06211478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Vitamin E will be taken for 6 months for gaucher disease patients who have oxidative stress and vitamin E defecient
Study NCT05408949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single exercise into pain (SEP) program
Description: * Baseline assessment \& commencement of treatment: Resisted isometric shoulder abduction into pain (or lateral rotation or flexion into pain) against a wall, or Resisted shoulder abduction from 0 to 30° using moderate resistance from Theraband ( Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~* Initial follow-up \& progression: Resisted shoulder abduction into pain from 80 to 120° using light weight (Prescribed High intensity loading to the tendon (85-90% iMVC) applied in 5 repetitions with a 45 secoud hold (3 times per week)).~* Second follow-up \& progression: eccentric shoulder abduction into pain from 80 to 120° with progressively increasing repetition and weight, e.g. heavy Theraband or dumbbell.~* Final assessment to identify any non-resolved functional limitations and progress eccentric exercises into pain as required~* Functional rehabilitation program
Study NCT05408949 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder Symptom Modification Procedure (SSMP)
Description: \[1\] Finger on the sternum,\[2A\] Scapula modification \[3\] 'Humeral head' modification \[4\] Isometric (most painful movement) Heavy slow resistance (HSR): start from the mid-range and pain-free
Study NCT05408949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Rehabilitation Program
Description: Mostly targetted into exercise such as multi-stage pushing, pulling, lifting and carrying, throwing, kinetic chain exercises and aerobics. FR involved (i). Weight-shifting activities to enhance dynamic joint stability\[18\] .(ii). Proprioceptive neuromuscular facilitation exercises to stimulating stretch receptors located on the muscle or tendon units \[18\]. Using resistive tubing exercises in a functional position using PNF patterns; diagonal pattern 1: flexion, abduction, external rotation (10-15 repetition 2-3 sets). (iii) Plyometric exercise: (A) throwing motions; (B) push-up (10-15 repetition 2-3 sets) . (iv). Table slide (10-15 repetition 2-3 sets).
Study NCT03863288 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Functional MRI (fMRI)
Description: Functional MRI (fMRI) scan with affective/cognitive tasks
Study NCT03863288 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional MRI (fMRI)
Description: Functional MRI (fMRI) scan with affective/cognitive tasks
Study NCT05436522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
Study NCT05408949 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Functional Rehabilitation Program
Description: Mostly targetted into exercise such as multi-stage pushing, pulling, lifting and carrying, throwing, kinetic chain exercises and aerobics. FR involved (i). Weight-shifting activities to enhance dynamic joint stability\[18\] .(ii). Proprioceptive neuromuscular facilitation exercises to stimulating stretch receptors located on the muscle or tendon units \[18\]. Using resistive tubing exercises in a functional position using PNF patterns; diagonal pattern 1: flexion, abduction, external rotation (10-15 repetition 2-3 sets). (iii) Plyometric exercise: (A) throwing motions; (B) push-up (10-15 repetition 2-3 sets) . (iv). Table slide (10-15 repetition 2-3 sets).
Study NCT03863288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin Intranasal Spray 8 International Unit (8IU)
Description: Oxytocin intranasal spray liquid administration
Study NCT03863288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin intranasal spray 24 International Unit (24IU)
Description: Oxytocin intranasal spray liquid administration
Study NCT03863288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin intranasal spray 48 International Unit (48IU)
Description: Oxytocin intranasal spray liquid administration
Study NCT03863288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin intranasal spray 80 International Unit (80IU)
Description: Oxytocin intranasal spray liquid administration
Study NCT03863288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intranasal spray liquid administration
Study NCT06249555 — intervention group
Intervention type: DRUG
Intervention: Vedolizumab (VDZ)
Description: Participants will receive VDZ as part of routine care.
Study NCT06249555 — intervention group
Intervention type: DRUG
Intervention: Ustekinumab (UST)
Description: Participants will receive UST as part of routine care.
Study NCT06249555 — intervention group
Intervention type: DRUG
Intervention: Risankizumab (RISA)
Description: Participants will receive RISA as part of routine care.
Study NCT05132205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: Radiofrequency Ablation using RFMedical device.
Study NCT06398301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation Program
Description: A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase. Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of three domains will be utilized to maximize their synergistic anabolic effect.~The duration of program will be set at 4 weeks. All activities will be performed in dedicated suites at each site, under supervision of qualified health professionals.
Study NCT06159673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-204
Description: ACP-204 is a potent and selective antagonist/inverse agonist of 5-hydroxytryptamine (serotonin) receptor subtype 2A.
Study NCT06159673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ACP-204 matching placebo
Study NCT05436522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is administered intravenously for induction and maintenance of general anesthesia. The dose is titrated to maintain Bispectral Index value between 40 and 60.
Study NCT04110756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ChangeGradients
Description: In the proposed intervention, adolescents at the UCSF clinics who endorse alcohol use on the Health e-Check screen, a 5-minute confidential risk behavior module, will be randomly assigned to either the CHANGEGRADIENTS Intervention or Comparison (no intervention). The CHANGEGRADIENTS system will generate behavior change narrative episodes that are tailored to the adolescent (e.g. level of alcohol use) while also universally addressing a core set of topics related to health behavior change. Shortly following the clinic visit, through 4 weekly, 20 minute episodes, adolescent participants will interact with the CHANGEGRADIENTS health behavior change environment outside of clinic. Adolescents will complete a brief alcohol screening-past 7-day use-at the beginning of each episode. At the end of the final episode, the system will produce an individualized adolescent report that summarizes use of the CHANGEGRADIENTS modules as well as self-reported alcohol use since clinic visit baseline.
Study NCT05808608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: Anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)
Study NCT05808608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: An oral, small molecule, TKI selective for VEGFRs; 5mg bid orally
Study NCT05291091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten 10 mg
Description: Sevasemten is administered orally once per day
Study NCT05291091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten 5 mg
Description: Sevasemten is administered orally once per day
Study NCT05291091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten 12.5 mg
Description: Sevasemten is administered orally once per day
Study NCT05291091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally once per day
Study NCT05985044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care cO-ORDInatioN And sympTom managEment (CO-ORDINATE) Intervention
Description: The intervention consists of the following four components: i) needs assessment; ii) question prompt list; iii) goals discussion and; iv) symptom assessment and tracking. The intervention will start with the enrolment of a patient living with multimorbidity. The intervention consists of one in-person pre-discharge visit by the study team and four follow-up telephone calls (at 48 hours, 1 week, 4 weeks, and 6 weeks post-discharge).
Study NCT05577858 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Meat based
Description: Omnivorous diet following dietary guidelines
Study NCT05577858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulse based
Description: Lacto-ovo-vegetarian pulse-based diet following dietary guidelines
Study NCT05869955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-97540
Description: Specified dose on specified days
Study NCT05869955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days
Study NCT05869955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days
Study NCT05869955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Specified dose on specified days
Study NCT06215118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: BCMA-CD3 bispecific antibody
Study NCT06215118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: cereblon-modulating agent
Study NCT06205238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGA
Description: CGA is defined as a multidimensional interdisciplinary diagnostic process focused on determining a frail elderly person's medical, psychological and functional capability in order to develop a coordinated and integrated plan for treatment and long term follow up.
Study NCT06205238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CGA
Description: CGA is defined as a multidimensional interdisciplinary diagnostic process focused on determining a frail elderly person's medical, psychological and functional capability in order to develop a coordinated and integrated plan for treatment and long term follow up.
Study NCT06380517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luminopia
Description: dichoptic movies/shows shown through a virtual reality headset
Study NCT06380517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eye Patch
Description: Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye
Study NCT05571059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifetroban Sodium
Description: Once daily oral ifetroban
Study NCT05571059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo
Study NCT05971303 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires will be given to patients, interpreters and cancer car professionals with aims of delineating the attitudes and experiences of patients, interpreters and cancer care professionals involved in the care of oncology patients with gynecologic malignancies
Study NCT06780254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH-001
Description: capsules
Study NCT06780254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules
Study NCT06552793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autogenous partially demineralized dentin graft
Description: tooth cleaning : form decay, tartar, soft tissue debris, fillings, cement then cut into fragments (5×5 mm) and inserted into the milling device (Tooth Transformer, Milan, Italy). A disposable box containing disposable liquid solutions will be inserted into the device to ensure the demineralization of the graft with 0.1 M hydrochloric acid, 10% hydrogen peroxide, and demineralized water as a wash.The decontamination of the granules will take place through UVA rays and ultrasounds, with temperature variations always lower than 43 ◦C to avoid damage to proteins. After 25 min, particle graft biomaterials will be obtained. The particles size will range from 815 µm with peaks up to 1110 µm.
Study NCT06552793 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xenograft
Description: Cortico-cancallous Bovine powder
Study NCT04646746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% wheat
Description: 100 g of bread backed with 100% wheat
Study NCT04646746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50% nude barley and 50% wheat
Description: 100 g of bread backed with 50% nude barley and 50% wheat
Study NCT04646746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 75% nude barley and 25% wheat
Description: 100 g of bread backed with 75% of nude barley and 25% wheat
Study NCT04646746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50% gene-modified high-amylose barley and 50% wheat
Description: 100 g of bread backed with 50% gene-modified high-amylose barley and 50% wheat
Study NCT04748328 — intervention group
Intervention type: PROCEDURE
Intervention: ACL Reconstruction surgery and Rehabilitation Treatment
Description: ACL Reconstruction surgery is a procedure to treat ACL injury by replacing the torn ligament with another. ACL Rehabilitation treatment is a procedure to treat ACL injury by muscle strengthening and exercise
Study NCT05504187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP104
Description: KP104 will be administered.
Study NCT06412835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cooperative learning
Description: Students working in groups
Study NCT06788860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tri-directional Ultrasound-guided Needle Knife Release
Description: This procedure involves ultrasound-guided tri-directional needle knife release for the treatment of trigger finger. Local anesthesia using 3-5 ml of 1% lidocaine and 0.25% bupivacaine will be administered for patient comfort. It aims to ensure precise tissue dissection while minimizing risks and improving outcomes.~Device: Sonosite M-Turbo Ultrasound Machine with Linear Probe HFL38x (6-13 MHz) is used for real-time imaging during the procedure.
Study NCT05408949 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EPTL
Description: In EPTL it involves eccentric training in Full range (with dumbbells 15-10 RM) of Internal and external rotation at scapular plane elevation (0-45) degree and Flexion, Abduction, in full range (5 repetitions with a 45 second hold at slow speed) to target the series elastic component of the muscle .
Study NCT05408949 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HSR
Description: In HSR it involves eccentric training in mid-range of motion (with dumbbells 15-10 RM) targeting the contractile component of the muscles and improving mechanical strength. Additionally, when there is 90% pain reduction on NPRS functional rehabilitation program start and they follow the same program as Group A.
Study NCT05506085 — intervention group
Intervention type: DEVICE
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation of Globus Pallidus interna
Study NCT04688450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIGORIS Blood Pressure Management Clinical Decision Support System
Description: Software system to optimize tight blood pressure management during vasopressor infusion
Study NCT06787742 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: full pulpotomy
Description: access to dental pulp chamber under aseptic condition, collect blood sample using a micropipette for ELIZA test, stop bleeding using sodium hypochlorite 2.5%, pulpotomy dressing material over pulp stump and final restoration with resign modified glass ionomer and composite resign
Study NCT06784128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise Program
Description: All patients were administered a therapeutic exercise program that included passive, active-assisted, and active range of motion exercises, stretching, strengthening, and mobilization exercises based on their level of movement restriction and pain intensity for 5 sessions per week for 2 weeks under the supervision of an experienced physiotherapist.
Study NCT06784128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise Program
Description: All patients were administered a therapeutic exercise program that included passive, active-assisted, and active range of motion exercises, stretching, strengthening, and mobilization exercises based on their level of movement restriction and pain intensity for 5 sessions per week for 2 weeks under the supervision of an experienced physiotherapist.
Study NCT06784128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot Pack
Description: As part of the treatment protocol, a hot pack was applied to the affected shoulder area for 30 minutes prior to any other therapeutic interventions. This initial application of heat was intended to promote muscle relaxation, increase local blood circulation, and reduce joint stiffness, effectively preparing the shoulder for the subsequent treatments, including therapeutic exercise, TENS and TECAR therapy. The hot pack was maintained at a temperature between 40-45°C, which is considered optimal for achieving therapeutic heat without causing discomfort or skin irritation.